Singapore and Charleston, SC - Novotech, the leading Asia-Pacific biotech specialist CRO, has acquired US CRO NCGS as part of a service expansion program for its global base of clients.
Novotech, which has a reputation for delivering full-service, high-quality expedited clinical trials in Asia-Pacific, can now offer its biotech clients clinical services in the US to support later phase global studies.
NCGS, established in 1984 in South Carolina, is a privately held CRO with a biopharma client base. NCGS has a workforce of about 300 professionals across the US.
Novotech CEO Dr. John Moller said “We are very pleased to acquire such an impressive company with a strong history of quality and delivery in the United States.. The company’s growth is a real credit to the knowledge and expertise of founder Nancy Snowden and the exceptional team she has formed”.
“This is a strategic move to provide US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs.”
“Clients will receive seamless service, with a unified approach to systems and SOPs well developed” Moller said.
Nancy C.G. Snowden, Founder and CEO of NCGS said the company was excited about being part of the Novotech operations globally and supporting Novotech’s clients with their US clinical programs. We have a similar cultural fit and focus on excellence so joining Novotech will be seamless for our clients and Novotech’s clients. “Novotech and NCGS have a longstanding collaboration history of over a decade which will also support the seamless integration”, Snowden commented.
“NCGS focuses on complex areas of clinical development; oncology, hematology, infectious disease, and CNS in both adult and pediatric populations.
Our lean organizational structure, nimble operational model with utilization of highly tenured staff have been specifically designed to overcome the challenges inhibiting our industry today. We have the ability to pivot in real time as the needs of the trial evolve.”
Novotech serves biotechs globally leveraging deep relationships built with hundreds of Asia-Pacific sites over the last 25 years. NCGS compliments this with a broad US site base of hundreds of investigators with relationships spanning nearly four decades.
Novotech is internationally recognized as the leading Asia Pacific centred Biotech Contract Research Organization (CRO) with global execution capabilities.
Novotech is a clinical CRO with labs, phase I facilities, drug development consulting services and FDA regulatory expertise and has experience in over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biotech clients conducting clinical trials in Asia Pacific, the US and Europe. Novotech has over 3000 staff globally and 34 office locations.
For more information visit https://novotech-cro.com/contact